Skip to main content
Fig. 3 | Orphanet Journal of Rare Diseases

Fig. 3

From: Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial

Fig. 3

Urinary GAGs (Mean±SEM) are plotted vs weeks of treatment. The horizontal lines are the mean±SEM of urinary GAGs in 12 MPSI children after 12 months of laronidase therapy, with a range of 177-269 ug GAG/mg creatinine [4]

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172